The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine

Lung Cancer

Volumn 75, Issue 2, 2012, Pages 248-254

  Kao, Steven Chuan Hao ^a   Harvie, Rozelle ^b,c   Paturi, Florian ^b   Taylor, Robyn ^c   Davey, Ross ^b,c   Abraham, Rick ^d   Clarke, Stephen ^b,c   Marx, Gavin ^c   Cullen, Martin ^c   Kerestes, Zoltan ^b,c   Pavlakis, Nick ^b,c  

^a Asbestos Diseases Research Institute   (Australia)

^b Bill Walsh Cancer Research Laboratories   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

Anti angiogenesis; CRP; IL 6; Mesothelin; Mesothelioma; SIL 6R; Thalidomide; VEGF

Indexed keywords

C REACTIVE PROTEIN; CISPLATIN; GEMCITABINE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESOTHELIN; PEMETREXED; THALIDOMIDE; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; COHORT ANALYSIS; CONSTIPATION; CORRELATION ANALYSIS; DISEASE COURSE; DIZZINESS; DROWSINESS; DRUG DOSE ESCALATION; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEARING LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MONOTHERAPY; NAUSEA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RASH; SURVIVAL RATE; THROMBOPHLEBITIS; TINNITUS; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; C-REACTIVE PROTEIN; CISPLATIN; CLINICAL TRIALS, PHASE II AS TOPIC; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84855445647     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.06.007     Document Type: Article

References (47)

1. Robinson B.W., Musk A.W., Lake R.A. Malignant mesothelioma. Lancet 2005, 366:397-408.
2. Herndon J.E., Green M.R., Chahinian A.P., Corson J.M., Suzuki Y., Vogelzang N.J. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the cancer and Leukemia group B. Chest 1998, 113:723-731.
3. Byrne M., Davidson J., Musk A., Dewar J., van Hazel G., Buck M., et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999, 17:25-30.
4. Kumar-Singh S., Vermeulen P., Weyler J., Segers K., Weyn B., Van Daele A., et al. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol 1997, 182:211-216.
5. Gasparini G., Longo R., Fanelli M., Teicher B. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005, 23:1295-1311.
6. Hanahan D., Bergers G., Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumour angiogenesis in mice. J Clin Invest 2000, 105:1045-1047.
7. D'Amato R., Loughnan M., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994, 9:4082-4085.
8. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 2000, 341:1565-1571.
9. Franks M., Macpherson G., Figg W. Thalidomide. Lancet 2004, 363:1802-1811.
10. Ohta Y., Shridhar V., Bright R., Kalemkerian G., Du W., Carbone M., et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999, 81:54-61.
11. Filho A., Baltazar F., Bedrossian C., Michael C., Schmitt F. Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma. Diagn Cytopathol 2007, 35:786-791.
12. Nakano T., Chahinian A., Shinjo M., Tonomura A., Miyake M., Togawa N., et al. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 1998, 77:907-912.
13. Hedman M., Arnberg H., Wernlund J., Riska H., Brodin O. Tissue polypeptide antigen (TPA), hyaluronan and CA125 as serum markers in malignant mesothelioma. Anticancer Res 2003, 23:531-536.
14. Pettersson T., Froseth B., Riska H., Klockars M. Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest 1988, 94:1037-1039.
15. Schouwink H., Korse C., Bonfrer J., Hart A., Baas P. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 1999, 25:25-32.
16. Creaney J., Robinson B. Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am 2005, 19:1025.
17. Demirag F., Unsal E., Yilmaz A., Caglar A. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 2005, 128:3382-3387.
18. Hashimoto K., Ikeda Y., Korenaga D., Tanoue K., Hamatake M., Kawasaki K., et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005, 103:1856-1864.
19. Nijsten M., de Groot E., ten Duis H., Klasen H., Hack C., Aarden L. Serum levels of interleukin-6 and acute phase responses. Lancet 1987, 2:921.
20. Jones S., Horiuchi S., Topley N., Yamamoto N., Fuller G. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001, 15:43-58.
21. Scholler N., Fu N., Yang Y., Ye Z., Goodman G., Hellstrom K., et al. Sobuble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 1999, 96:11531-11536.
22. Beyer H., Geschwindt R., Glover C., Tran L., Hellstrom I., Hellstrom K., et al. MESOMARK™: a potential test for malignant pleural mesothelioma. Clin Chem 2007, 53:666-672.
23. Hollen P., Gralla R., Liepa A., Symanowski J., Rusthoven J. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation. Cancer 2004, 101:587-595.
24. Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15:257-260.
25. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
26. Curran D., Sahmoud T., Therasse P., van Meerbeeck J., Postmus P., Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998, 16:145-152.
27. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
28. Baas P., Boogerd W., Dalesio O., Haringhuizen A., Custers F., van Zandwijk N. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005, 48:291-296.
29. Baas P. NVALT5 Trial-phase 3 trial of the antiangiogenic agent thalidomide in patients with malignant mesothelioma after first line chemotherapy. Available at: 2006. http://www.trialregister.nl/trialreg/admin/rctview.asp%3FTC=798.
30. Baas P., Buikhuisen W., Vincent A., van Klaveren R., Custers F., Schouwink H., et al. Open label randomized phase III maintenance study of thalidomide (arm A) vs. observation (arm B) in patients with MPM after treatment with cisplatin and pemetrexed: interim report (abstr S10-2). Proceedings of the 10th International Conference of the International Mesothelioma Interest Group 2010, 135.
31. Lee S., Woll P., Rudd R., Ferry D., O'Brien M., Middleton G., et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2009, 101:1049-1057.
32. Pujol J., Breton J., Gervais R., Tanguy M., Quoix E., David P., et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 2007, 25:3945-3951.
33. Robinson B.W.S., Creaney J., Lake R., Nowak A., Musk A.W., de Klerk N., et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003, 362:1612-1616.
34. Karrison T., Kindler H.L., Gandara D.R., Lu C., Guterz T.L., Nichols K., et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J Clin Oncol 2007, 25(18S):7526.
35. Dowlati A., Gray R., Sandler A., Schiller J., Johnson D. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group study. Clin Cancer Res 2008, 14:1407-1412.
36. Poon R., Fan S., Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001, 19:1207-1225.
37. George M., Eccles S., Tutton M., Abulafi A., Swift R. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?. Clin Cancer Res 2000, 6:3147-3152.
38. Lee J., Hong Y., Han C., Hwang D., Hong S. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?. Int J Oncol 2000, 17:149-152.
39. Pinedo H., Verheul H.M., D'Amato R., Folkman J. Involvement of platelets in tumour angiogenesis?. Lancet 1998, 352:1775-1777.
40. Verheul H., Hoekman K., Luykx-de Bakker S., Eekman C., Folman C., Broxterman H., et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997, 3:2187-2190.
41. Wynendaele W., Derua R., Hoylaerts M., Pawinski A., Waelkens E., de Bruijn E., et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?. Ann Oncol 1999, 10:965-971.
42. Hormbrey E., Gillespie P., Turner K., Han C., Roberts A., McGrouther D., et al. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful?. Clin Exp Metastasis 2002, 19:651-663.
43. Ganapathi M., May L., Schultz D., Brabenec A., Weinstein J., Sehgal P., et al. Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines. Biochem Biophys Res Commun 1988, 157:271-277.
44. Jones S., Novick D., Horiuchi S. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med 1999, 189:599-604.
45. McKeown D., Brown D., Kelly A., Wallace A., McMillan D. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer 2004, 19:1993-1995.
46. Jones S., Rose-John S. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta 2002, 1592:251-263.
47. Hassan R., Bera T., Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004, 10:3937-3942.